Metrika članka

  • citati u SCindeksu: [1]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:105
  • preuzimanja u poslednjih 30 dana:97
članak: 8 od 34  
Back povratak na rezultate
Hemijska industrija
2013, vol. 67, br. 1, str. 17-25
jezik rada: srpski
vrsta rada: stručni članak
doi:10.2298/HEMIND120410057M


Milrinon svojstva i sinteza
Univerzitet u Beogradu, Tehnološko-metalurški fakultet

e-adresa: jmirkovic@tmf.bg.ac.rs

Projekat

Proučavanje sinteze, strukture i aktivnosti organskih jedinjenja prirodnog i sintetskog porekla (MPNTR - 172013)

Sažetak

Milrinon (Primacor®, Corotrop®, Corotrope® ili Milrila®) pripada grupi bipiridinskih kardiotonika i vazodilatatora koji selektivno inhibiraju enzim fosfodiesterazu 3 (PDE-3). Primenjuje se u terapiji kongestivne srčane insuficijencije dugi niz godina. Mirlinon hemijski predstavlja 1,6-dihidro-2-metil-6-okso-(3,4’-bipiridin)-5-karbonitril-laktat. U literaturi postoje podaci o mogućem letalnom ishodu prilikom dugotrajne oralne primene ovog leka, zbog čega se daje intravenski, u kratkom vremenskom periodu. U radu je, na osnovu literaturnih podataka, dat pregled osnovnih svojstava, mehanizam delovanja i stabilnost milrinona, kao i načini za njegovo laboratorijsko i industrijsko dobijanje. Na kraju je dat način prečišćavanja kao i postupak izrade injekcija.

Ključne reči

Reference

*** Analysis of drugs and poisons. (pristupljeno 15. 03. 2012)
*** (2007) United States Pharmacopeia 30: National Formulary 25. str. 2665
*** (2008) AHFS Drug Information
Ahn, H.S., Eardley, D., Watkins, R., Prioli, N. (1986) Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism. Biochemical Pharmacology, 35(7): 1113-1121
Akkerman, S.R., Zhang, H., Mullins, R.E., Yaughn, K. (1999) Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i. v. solutions. Am. J. Health Syst. Pharm., 56; 329105; 130(1999): 63-68
Alousi, A.A., Canter, J.M., Montenaro, M.J., Fort, D.J., Ferrari, R.A. (1983) Cardiotonic Activity of Milrinone, a New and Potent Cardiac Bipyridine, on the Normal and Failing Heart of Experimental Animals. Journal of Cardiovascular Pharmacology, 5(5): 792-803
Baxter, K. (2008) Stockleys drug interaction. London: Pharmaceutical Press, str. 698, 1179
Borow, K.M., Come, P.C., Neumann, A., Baim, D.S., Braunwald, E., Grossman, W. (1985) Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease. American Journal of Cardiology, 55(9): 1204-1209
Braunwald, E. (1981) Heart failure: Pathophysiology and treatment. American Heart Journal, 102(3): 486-490
Casanova, M.J.V. (1986) Process for the preparation of 1, 2 dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinonitrile. ES 548691
Chen, P., Tan, Y., Zhu, Z., Wu, X., Lei, S. (2006) New freeze-dried injection powder formulation of milrinone (Faming Zhuanli Shenqing). CN 1879622 [CA 146:128551 (2006)]
Chen, S., Yang, J., Jin, Q., Liu, D., Zhao, L. (2009) Improved syn thesis of milrinone. Zhongguo Yaowu Huaxue Zazhi, 19; 262099; 154(2010): 261-262
Dai, X., Guo, P., Li, L. (2007) Purification of 1,6-dihydro-2-methyl6-oxo-[3,4’-bipyridine]-5-carbonirile (milrinone) and synthesis of its USP impurity A (i.e., 1,6-dihydro-2-methyl-6-oxo-[3,4’-bipyridine]-5-carboxamide). Zhongguo Yaoxue Zazhi, 42, str. 1436-1437 [CA 150:539531 (2008)]
Dorigo, P., Fraccarollo, D., Santostasi, G., Gaion, R.M., Maragno, I., Floreani, M., Carpenedo, F., Jester, M., Mosti, L., Schenone, P. (1994) Pharmacological characterization of a new milrinone analogue. Farmaco, 49(1): 19-23
Dorigo, P., Gaion, R.M., Belluco, P., Borea, P.A., Guerra, L., Mosti, L., Floreani, M., Carpenedo, F. (1992) Antagonism towards endogenous adenosine and inhibition of cGI-PDE in the cardiac effects of amrinone, milrinone and related analogues. General Pharmacology: the Vascular System, 23(3): 535-541
Dorigo, P., Gaion, R.M., Belluco, P., Fraccarollo, D., Maragno, I., Bombieri, G., Benetollo, F., Mosti, L., Orsini, F. (1993) A pharmacological, crystallographic, and quantum chemical study of new inotropic agents. Journal of Medicinal Chemistry, 36(17): 2475-2484
Faba, D.E.M. (1986) Process for the preparation of 1, 6-dihydro 2-methyl-6-oxo-3, 4-bipyridine-5-carbonitrile. Can Pelegeri: Pol. Ind, ES 544504
Farah, A.E., Alousi, A.A. (1978) New cardiotonic agents: A search for digitalis substitute. Life Sciences, 22(13-15): 1139-1147
Forest, M.C., Lahouratate, P., Martin, M., Nadler, G., Quiniou, M.J., Zimmermann, R.G. (1992) A novel class of cardiotonic agents: synthesis and biological evaluation of 5-substituted 3,6-dihydrothiadiazin-2-ones with cyclic AMP phosphodiesterase inhibiting and myofibrillar calcium sensitizing properties. Journal of Medicinal Chemistry, 35(1): 163-172
Fujino, K., Sperelakis, N., Solaro, R.J. (1988) Differential effects of d- and l-pimobendan on cardiac myofilament calcium sensitivity. Journal of pharmacology and experimental therapeutics, 247(2): 519-23
Gao, H., Wu, N., Yang, J., Jin, Q., Huang, W. (2009) Improvement on synthesis process of 1-(4-pirydinyl)-2-propanone. Huaxue Gongye Yu Gongcheng Jishu, 30 17-18 [CA 153:11445 (2009)]
Gelotte, K.O. (1984) Process for preparing 2-(lower-alkoxy)-1(pyridinyl) ethenyl lower-alkyl ketones. Sterling Drug Inc, US 4469871
Hagen, V., Klauschenz, E., Jaensch, H.J., Niedrich, H., Heidrich, H.J., Faust, G., Lohmann, D. (1990) Preparation of 5-aryl1, 2-dihydropyrid-2-ones as cardiotonics. Akademie der Wissenschaften, DD 275047
Jaensch, H.J., Heidrich, H.J., Schaefer, J., Dietz, G., Hagen, V., Klauschenz, E., Lohmann, D. (1988) Preparation of milrinone. Dresden: Arzneimittelwerk, DD 274620
Lathers, C.M., Roberts, J. (1980) Digitalis cardiotoxicity revisited. Life Sciences, 27(19): 1713-1733
Lesher, G.Y., Philion, R.E. (1982) 3-substituted-6-(lower-alkyl) 5-(pyridinyl)-2-(1H)-pyridones, their cardiotonic use and intermediates therefor. Sterling Drug Inc, US 4313951
Lesher, G.Y., Philion, R.E., Page, D.F., Opalka, C.J. (1981) 5-(py ridinyl)2(1H)pyridones useful as cardiotonic agents. Sterling Drug Inc, FR 2470124
Lesher, G.Y., Opalka, C.J., Page, D.F. (1982) 5-(pyridinyl)-6(lower-alkyl)-2(1H)-pyridones, 1, 2-dihydro-2-oxo-5-(pyridinyl)-6-(lower-alkyl)nicotinic acids and lower-alkyl esters thereof, and cardiotonic use thereof. Sterling Drug Inc, US 4312875
Lesher, G.Y., Philion, R.E., Page, D.F., Opalka, C.J. (1981) 5-(pyri dinyl)-2(1H)-pyridones, useful as cardiotonic agents and their preparation. Sterling Drug Inc, GB 2065642A
Linan, I.C., Mir, M.O. (1986) Process for the preparation of 1, 6 dihydro-2-methyl-6-oxo-3, 4-bipyridine-5-carbonitrile. Pol. Ind. Palafolis, ES 543212
Liu, Q., Su, Y., Chen, B., Zhang, H. (2005) Synthesis and structural identification of phosphodiesterase inhibitor milrinone. Huazhong Keji Daxue Xuebao, 34 74-75 [CA 145:29803 (2005)]
Muller, J.E., Turi, Z.G., Stone, P.H., Rude, R.E., Raabe, D.S., Jaffe, A.S., Gold, H.K., Gustafson, N., Poole, W.K., Passamani, E., Smith, T.W., Braunwald, E., Group The MILIS Study (1986) Digoxin Therapy and Mortality after Myocardial Infarction. New England Journal of Medicine, 314(5): 265-271
Murakami, R., Sano, K., Murakami, Y., Shimada, T., Morioka, S. (1995) Effects of intracoronary infusion of an inotropic agent, E-1020 (loprinone hydrochloride), on cardiac function: evaluation of left ventricular contractile performance using the end-systolic pressure-volume relationship. International Journal of Cardiology, 51(1): 57-63
Pastelin, G., Mendez, R., Kabela, E., Farah, A. (1983) The search for a digitalis substitute II milrinone (Win 47203) its action on the heart-lung preparation of the dog. Life Sciences, 33(18): 1787-1796
Ren, B., Zhang, J., Zhang, M., Xu, X. (2006) Milrinone composition for injection (Faming Zhuanli Shenqing Gongkai Shuomingshu). CN 1739512 [CA 144:456434 (2006)]
Riley, C.M. (1988) Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propanolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am. J. Hosp. Pharm., 45; 82362; 110(1989): 2079-2091
Robertson, D.W., Beedle, E.E., Swartzendruber, J.K., Jones, N.D., Elzey, T.K., Kauffman, R.F., Wilson, H., Hayes, S. (1986) Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone. Journal of Medicinal Chemistry, 29(5): 635-640
Rosowsky, A., Forsch, R.A., Freisheim, J.H., Moran, R.G. (1989) The 2-desamino and 2-desamino-2-methyl analogs of aminopterin do not inhibit dihydrofolate reductase but are potently toxic to tumor cells in culture. Journal of Medicinal Chemistry, 32(3): 517-520
Shiao, M., Shyu, L., Chen, C. (1990) Synthesis of Milrinone, a Cardiotonic Agent. Heterocycles, 31(3): 523
Singh, B. (1983) Preparation of 1, 2-dihydro-6-(lower alkyl)-2 oxo-5-(pyridinyl)-nicotinonitriles. Sterling Drug Inc, US 4413127
Singh, B. (1985) A Novel Synthesis of 1,6-Dihydro-2-methyl-6-oxo[3,4'-bipyridine]-5-carbonitrile (Milrinone). Heterocycles, 23(6): 1479
Singh, B., Lesher, G.Y., Pluncket, K.C., Pagani, E.D., Bode, D.C., Bentley, R.G., Connell, M.J., Hamel, L.T., Silver, P.J. (1992) Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones. Journal of Medicinal Chemistry, 35(26): 4858-4865
Su, Y.F., Harden, T.K., Perkins, J.P. (1980) Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process. Journal of biological chemistry, 255(15): 7410-9
Sweetman, S.C. (2009) Martindale. London: Pharmaceutical Press, pp. 1341-1342; 36th ed
Wilson, T.D., Forde, M.D. (1990) Stability of milrinone and epinephrine, atropine sulfate, lidocain hydrochloride, or morphine sulfate injection. Am. J. Hosp. Pharm., 47; 68946; 114(1991): 2504-2507
Wilson, T.D., Forde, M.D., Crain, A.V., Dombrowski, L.J., Joyce, M.A. (1986) Stability of milrinone in O. 45% sodium chloride, O. 9% sodium chloride, or 5% dextrose injections. Am. J. Hosp. Pharm., 43; 178336; 105(1986): 2218-2220
Xu, F., Ren, J., Chen, J., Liao, Q. (1996) Synthesis of milrinone. Zhongguo Yaoke Daxue Xuebao, 27; 328468; 125(1996): 377-378
Xue, K., Liu, A. (2007) Method for preparing water-soluble milrinone salt from milrinone. Faming Zhuanli Shenqing Gongkai Shuomingshu, CN 1951919 [CA 146:528220]
Yano, M., Kohno, M., Ohkusa, T., Mochizuki, M., Yamada, J., Kohno, M., Hisaoka, T., Ono, K., Tanigawa, T., Kobayashi, S., Matsuzaki, M. (2000) Effect of milrinone on left ventricular relaxation and Ca2+ uptake function of cardiac sarcoplasmic reticulum. Am. J. Physiol. Heart Circ. Physiol., 279(905): H1-898
Yusuf, S., Wittes, J., Bailey, K., Furberg, C. (1986) Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods. Circulation, 73(1): 14-18
Zhang, L. (2008) Method for preparing milrinone lactate. Faming Zhuanli Shenqing Gongkai Shuomingshu, CN 101143844 [CA 148:449458]
Zhang, L. (2008) Freeze-dried powder injection of milrinone lactate for treating heart failure and its preparation. Faming Zhuanli Shenqing, CN 101143144 [CA 148:387240]
Zhang, W., Tian, L., Wang, S., Liu, R. (1999) Novel synthesis of 1 (4-pirydinyl)-2-propanone. Shenyang Yaoke Daxue Xuebao, 16 296-297 [CA 132:122486 (1999)]
Zhao, Z. (2005) Milrinone and sodium chloride injection and its preparation method (Faming Zhuanli Shenqing Gongkai Shuomingshu). CN 1679566 [CA 145:51029 (2006)]
Zhao, Z. (2005) Manufacture of freeze-dried powder injection containing milrinone (Faming Zhuanli Shenqing Gongkai Shuomingshu). CN 1709441 [CA 145:404310 (2006)]
Zhao, Z. (2005) Process for the preparation of milrinone (Faming Zhuanli Shenqing Gongkai Shuomingshu). CN 1629141 [CA 144:128860 (2006)]
Zheng, X., Feng, Z., Liu, Y. (1990) Synthesis of milrinone. Zhong guo Yiyao Gongye Zazhi, 21; 8524; 115(1991): 486-488